PFE - Pfizer Inc.

NYSE - Nasdaq Real Time Price. Currency in USD
35.780
+0.140 (+0.39%)
As of 1:35PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close35.640
Open35.710
Bid35.800 x 800
Ask35.810 x 4000
Day's Range35.520 - 35.870
52 Week Range31.670 - 39.430
Volume7,666,673
Avg. Volume21,990,058
Market Cap209.298B
Beta0.95
PE Ratio (TTM)9.94
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.36 (3.82%)
Ex-Dividend Date2018-05-10
1y Target EstN/A
Trade prices are not sourced from all markets
  • A Look into Roche Holding’s Performance in Q1 2018
    Market Realist6 hours ago

    A Look into Roche Holding’s Performance in Q1 2018

    In the first quarter, Roche Holding (RHHBY) reported revenues of ~13.6 billion Swiss francs compared to ~12.9 billion Swiss francs in the first quarter of 2017, which reflected ~5.0% growth on a YoY (year-over-year) basis.

  • Pfizer's Epilepsy Drug Lyrica Succeeds in Pediatric Study
    Zacks3 days ago

    Pfizer's Epilepsy Drug Lyrica Succeeds in Pediatric Study

    Pfizer (PFE) announces positive top-line results from a phase III study in pediatric epilepsy wherein Lyrica Oral Solution CV meets its primary endpoint.

  • Eli Lilly’s Valuation on May 17
    Market Realist3 days ago

    Eli Lilly’s Valuation on May 17

    Eli Lilly (LLY) reported EPS of $1.34 and revenues of $5.7 billion in the first quarter. Both results surpassed Wall Street analysts’ estimates.

  • Pharma Stock Roundup: Zoetis to Buy Abaxis, NVS Gets FDA Nod for Migraine Drug
    Zacks3 days ago

    Pharma Stock Roundup: Zoetis to Buy Abaxis, NVS Gets FDA Nod for Migraine Drug

    Novartis' (NVS) CGRP antibody, Aimovig gains FDA approval for prevention of migraine. Zoetis (ZTS) and Lilly (LLY) announce deals to buy smaller companies.

  • Exelixis Is Focused on Management of the Cabozantinib Franchise
    Market Realist3 days ago

    Exelixis Is Focused on Management of the Cabozantinib Franchise

    Exelixis (EXEL) is focused on the label expansion and life cycle management of the cabozantinib franchise in collaboration with Bristol-Myers Squibb (BMY) and Roche Holdings (RHHBY). The above diagram shows the rationale for studying cabozantinib in combination with immunotherapy in multiple cancer indications. Exelixis is currently evaluating the safety and preliminary activity, in terms of objective response rate and progression-free survival, of a combination of cabozantinib with nivolumab and a combination of cabozantinib with nivolumab and ipilimumab in advanced hepatocellular carcinoma (or HCC) indications in an ongoing Phase 2 trial.

  • Label Expansion May Boost Cabometyx’s Revenue in 2018
    Market Realist3 days ago

    Label Expansion May Boost Cabometyx’s Revenue in 2018

    On January 16, Exelixis (EXEL) and Ipsen announced positive results from the CELESTIAL Phase 3 trial highlighting the statistically significant and clinically meaningful improvement in the trial’s primary end point of overall survival due to cabozantinib therapy compared to a placebo in second-line and third-line hepatocellular carcinoma (or HCC) patients.

  • Cabometyx Is Expected to Witness a Robust Revenue Rise in 2018
    Market Realist3 days ago

    Cabometyx Is Expected to Witness a Robust Revenue Rise in 2018

    In the first quarter, Exelixis’s (EXEL) Cabometyx witnessed more than a 20% sequential rise in prescription volume driven by both new patient starts and a robust rise in the total number of patients on the therapy. According to a report, ~295,000 people across the world are diagnosed with kidney cancer every year, while 134,000 kidney cancer patients die every year. According to the American Cancer Society’s Cancer Facts & Figures 2018, the annual incidence of kidney cancer in the United States is ~65,000, while the annual death toll of the disease is 15,000. Another report estimates that almost 70%–75% of renal cell cancer (or RCC) patients suffer from clear cell RCC.

  • Financial Times3 days ago

    [$$] AstraZeneca chief Pascal Soriot suffers pay revolt

    suffered a significant revolt over the pay of its chief executive Pascal Soriot on Friday, when about 35 per cent of shareholders at its annual meeting voted against its remuneration report. Mr Soriot earned £9.4m in 2017, down from £14.3m a year earlier, but ISS had complained about the level of annual bonuses he had received, suggesting that the remuneration committee should have set more stringent targets. Pointing to the sales the company is garnering from its new medicines, one insider said that Mr Soriot was being “rewarded for turning science into products”.

  • Exelixis Focused on Positioning Cabometyx in Kidney Cancer Space
    Market Realist4 days ago

    Exelixis Focused on Positioning Cabometyx in Kidney Cancer Space

    Exelixis (EXEL) aims to position Cabometyx as the preferred tyrosine-kinase inhibitor (or TKI) in the renal cell carcinoma (or RCC) segment. At the end of 2017, Cabometyx had managed to acquire a 42% share of the second-line and new patient advanced RCC market, higher than its 39% market share at the end of the third quarter of 2017. Cabometyx demonstrated superiority over Pfizer’s (PFE) Sutent as a first-line RCC therapy in its Phase 2 CABOSUN trial in terms of progression-free survival, which has helped boost physicians’ confidence in Cabometyx.

  • InvestorPlace4 days ago

    Investors Need to Adopt a Different Mindset for Big Pharma and Biotech Stocks

    The ability to sell new drugs hinges on approvals from government bodies such as the Food and Drug Administration (FDA). As a result, biotech companies, and to some degree, large drug companies, go into business ventures without the certainty of ever earning revenues, let alone profits. Biotech stocks often become some of the most difficult to evaluate.

  • Sangamo Therapeutics Stock History
    Motley Fool4 days ago

    Sangamo Therapeutics Stock History

    After decades of research into gene editing, this biotech company could be on the cusp of developing game-changing new treatments for rare diseases.

  • Taking Stock of Gilead Sciences’ Key Developments
    Market Realist4 days ago

    Taking Stock of Gilead Sciences’ Key Developments

    During the first quarter, Gilead Sciences (GILD) entered into a scientific collaboration with Verily Life Sciences to identify and better understand the immunological basis of three common, serious inflammatory diseases—rheumatoid arthritis, inflammatory bowel disease, and lupus-related diseases—by making use of Verily’s Immunoscape platform.

  • Exelixis Is Expected to Report a Robust Revenue Rise in 2018
    Market Realist4 days ago

    Exelixis Is Expected to Report a Robust Revenue Rise in 2018

    The company reported net income of close to $115.9 million in the quarter, a YoY rise of ~594% and a sequential rise of 201%. Exelixis reported diluted GAAP (generally accepted accounting principles) EPS (earnings per share) of close to $0.37, a YoY rise of ~585% and a sequential rise of 201%. Analysts expect Exelixis to report revenue of close to $723 million in 2018, a YoY rise of ~59.8%.

  • Roche Tecentriq Combo Achieves Longer Overall Survival Rate
    Zacks4 days ago

    Roche Tecentriq Combo Achieves Longer Overall Survival Rate

    Roche's (RHHBY) immuno-oncology drug, Tecentriq, in combination with Avastin and chemotherapies leads to significantly longer overall survival rates in treatment-naive NSCLC patients.

  • Exelixis' Cabometyx Gets EU Nod for First-Line Kidney Cancer
    Zacks4 days ago

    Exelixis' Cabometyx Gets EU Nod for First-Line Kidney Cancer

    European Commission approves Exelixis' (EXEL) Cabometyx 20 mg, 40 mg and 60 mg for the first-line treatment of adults with intermediate- or poor-risk renal cell carcinoma in the European Union.

  • Gilead Sciences’ Cash Flows, Valuations, and Price Performance
    Market Realist4 days ago

    Gilead Sciences’ Cash Flows, Valuations, and Price Performance

    Gilead Sciences (GILD) stock has corrected 9.6% since the start of 2018 to close at $66.99 on May 15. In comparison, Johnson & Johnson (JNJ), Pfizer (PFE), and Merck & Co. (MRK) have returned -9.5%, -2.1%, and 5.3%, respectively.

  • Why Exelixis Stock Fell Last Week
    Market Realist4 days ago

    Why Exelixis Stock Fell Last Week

    On May 11, Exelixis’s (EXEL) closing price was $19.55, almost 12.9% lower than its closing price on May 4. This fall was mainly attributable to unfavorable results released from its Phase 3 IMblaze370 study comparing a combination regimen of Cotellic (cobimetinib) with Roche Holdings’ (RHHBY) Tecentriq (atezolizumab) compared to Bayer’s Stivarga in locally advanced or metastatic colorectal cancer indications. Exelixis and Roche Holdings’ investigational combination regimen failed to demonstrate a statistically significant improvement in the primary end point of overall survival compared to Stivarga in difficult-to-treat patients who had witnessed disease progression or had been unable to tolerate at least two chemotherapy treatments.

  • Teva’s Fiscal Guidance: Confidence in Its Growth
    Market Realist4 days ago

    Teva’s Fiscal Guidance: Confidence in Its Growth

    Teva Pharmaceutical (TEVA) provided an increased guidance for this fiscal year during its first-quarter earnings release on May 3. The company has made an upward revision to its guidance for this fiscal year. Teva reported better-than-expected results in the fiscal first quarter.

  • Is Alnylam Pharmaceuticals, Inc. (ALNY) a Buy?
    Motley Fool4 days ago

    Is Alnylam Pharmaceuticals, Inc. (ALNY) a Buy?

    Good news for Pfizer muddies the waters somewhat for Alnylam's outlook.

  • 5 Companies To Watch As Marijuana Legalization Approaches
    Oilprice.com5 days ago

    5 Companies To Watch As Marijuana Legalization Approaches

    Canada is about to become the first major industrialized nation to legalize marijuana use across the country, and the companies that have positioned themselves to profit could see remarkable gains

  • Gilead Sciences Stock: How Much Upside Do Analysts Expect?
    Market Realist5 days ago

    Gilead Sciences Stock: How Much Upside Do Analysts Expect?

    Gilead Sciences (GILD) is a research-based biopharmaceutical company focused on discovering, developing, and bringing to market innovative medicines for life-threatening diseases. Gilead released its first-quarter earnings on May 4. Of the 26 analysts covering Gilead Sciences stock in May, 16 of them have given the stock a “buy” or higher rating, and ten have given it a “hold.” The mean rating for the stock is 2.2 with a target price of $85.81, which implies an upside potential of 27.2% over its closing price of $66.99 on May 15.

  • Pfizer Gets FDA Nod for Amgen, J&J's Anemia Drug Biosimilar
    Zacks5 days ago

    Pfizer Gets FDA Nod for Amgen, J&J's Anemia Drug Biosimilar

    Pfizer's (PFE) Retacrit, a biosimilar of Amgen's Epogen and J&J's Procrit gets FDA approval. The drug will be available for the treatment of anemia.

  • Reuters6 days ago

    Pfizer's biosimilar of Amgen, J&J's anemia treatments gets FDA nod

    Pfizer Inc's Retacrit was approved by U.S. health regulators as a biosimilar to current anemia treatments from Amgen Inc and Johnson & Johnson on Tuesday, setting it up to compete against more established brands. A year ago the U.S. Food and Drug Administration rejected Retacrit as a copy of Amgen's Epogen and Johnson & Johnson's Procrit, citing https://investors.pfizer.com/investor-news/press-release-details/2017/Pfizer-Provides-Update-on-Proposed-Epoetin-Alfa-Biosimilar/default.aspx issues with a potential manufacturing facility in Kansas.

  • AstraZeneca’s 1Q18 Estimates: Segment-by-Segment Revenues
    Market Realist6 days ago

    AstraZeneca’s 1Q18 Estimates: Segment-by-Segment Revenues

    As we discussed in the previous article, AstraZeneca’s (AZN) revenue is expected to report a 2.3% fall to $5.3 billion in 1Q18 compared to $5.4 billion in 1Q17.

  • Reuters6 days ago

    FDA approves Pfizer's biosimilar of Amgen's Epogen

    The U.S. Food and Drug Administration on Tuesday approved Pfizer Inc's biosimilar of Amgen Inc's anemia treatment Epogen. The biosimilar, called Retacrit, was approved to treat anemia caused by chronic ...